Download Download this free, 150-page Pharmaceutical Serialization Playbook jam-packed with strategies for success and pitfalls to avoid.  Learn more >>
Article |

Eclipsing the competition

Recently approved by the U.S. Food and Drug Administration for OTC sales, SmithKline Beecham's new Tagamet HB is one of the first "Acid blocker" products to reach the re-tail market.
FILED IN:  Applications  > Healthcare  > Pharmaceutical

Introduced nationally last month powerful folding carton gra-phics provide quite a departure from the predominately white ap-proach typically taken with drug products. "We found that this design did a great job of catching the consumer's eye" says Paul Madzik senior product manager at Philadelphia PA-based SmithKline Beecham. "We think it communicates the right image for Tagamet: It's a breakthrough in advanced medicine a revolutionary and very unique product." Created by SBG Partners (San Francisco CA) a solar eclipse design alludes to the product's ability to prevent acids from forming in the stomach. "We were looking for a graphic symbol that could quickly signal how powerful Tagamet HB is in reducing heartburn" explained Flavio Gomez senior managing partner of SBG Partners. To further differentiate the package the eclipse is positioned against a navy blue background. At press time supplier information was not available from SmithKline. Tagamet HB is available in 16- 32- and 64-count packages.

Related Sponsored Content

E-Book Special Report
Total Cost of Ownership
Sign up to receive timely updates from our editors and download this E-Book Special Report to learn how to calculate the true Total Cost of Ownership (TCO) of your packaging machinery.


Don't miss intelligence crucial to your job and business!
Click on any newsletter to view a sample. Enter your email address below to sign up!
Each newsletter ranges in frequency from once per month to a few times per month at most.